DAIHAN PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28,800 KRW | +0.88% |
|
+0.70% | +3.78% |
| 2023 | Daihan Pharmaceutical Co.,Ltd.(KOSDAQ:A023910) dropped from S&P Global BMI Index | CI |
| 2023 | Daihan Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 189,900 | 197,700 | 172,200 | 183,600 | 163,170 | 169,344 | - |
| Enterprise Value (EV) 2 | 167.8 | 197.7 | 105.1 | 92.49 | 58.81 | 31.34 | 6.144 |
| P/E ratio | 6.74 x | 11.4 x | 7.6 x | 7.34 x | 5.74 x | 5.61 x | 5.21 x |
| Yield | 1.26% | - | 1.39% | 2.12% | 2.7% | 2.43% | 2.52% |
| Capitalization / Revenue | 1.13 x | 1.19 x | 1 x | 1 x | 0.83 x | 0.8 x | 0.73 x |
| EV / Revenue | 0.99 x | 1.19 x | 0.61 x | 0.5 x | 0.3 x | 0.15 x | 0.03 x |
| EV / EBITDA | 3.78 x | 4.79 x | 2.6 x | 2.19 x | 1.32 x | 0.66 x | 0.12 x |
| EV / FCF | - | - | - | - | 3.35 x | 1.05 x | 0.19 x |
| FCF Yield | - | - | - | - | 29.9% | 95.1% | 519% |
| Price to Book | 1.14 x | - | 0.85 x | 0.81 x | 0.66 x | 0.62 x | 0.56 x |
| Nbr of stocks (in thousands) | 6,000 | 6,000 | 6,000 | 6,000 | 5,880 | 5,880 | - |
| Reference price 3 | 31,650 | 32,950 | 28,700 | 30,600 | 27,750 | 28,800 | 28,800 |
| Announcement Date | 30/03/20 | 16/03/21 | 09/02/22 | 28/02/23 | 20/03/24 | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 168.8 | 166.1 | 171.5 | 184.3 | 195.9 | 212.8 | 232.6 |
| EBITDA 1 | 44.42 | 41.26 | 40.48 | 42.18 | 44.46 | 47.75 | 50.45 |
| EBIT 1 | 33.64 | 29.96 | 29.07 | 32.97 | 35.8 | 38.4 | 41.15 |
| Operating Margin | 19.93% | 18.04% | 16.95% | 17.89% | 18.27% | 18.04% | 17.69% |
| Earnings before Tax (EBT) 1 | 37.13 | 22.53 | 30.43 | 33.45 | 36.73 | 39.6 | 42.7 |
| Net income 1 | 28.17 | 17.38 | 22.67 | 24.96 | 28.43 | 30.8 | 33.2 |
| Net margin | 16.69% | 10.47% | 13.22% | 13.55% | 14.51% | 14.47% | 14.27% |
| EPS 2 | 4,694 | 2,897 | 3,778 | 4,171 | 4,834 | 5,132 | 5,533 |
| Free Cash Flow 3 | - | - | - | - | 17,580 | 29,800 | 31,900 |
| FCF margin | - | - | - | - | 8,973.42% | 14,000.47% | 13,714.53% |
| FCF Conversion (EBITDA) | - | - | - | - | 39,542.23% | 62,408.38% | 63,230.92% |
| FCF Conversion (Net income) | - | - | - | - | 61,843.97% | 96,753.25% | 96,084.34% |
| Dividend per Share 2 | 400.0 | - | 400.0 | 650.0 | 750.0 | 700.0 | 725.0 |
| Announcement Date | 30/03/20 | 16/03/21 | 09/02/22 | 28/02/23 | 20/03/24 | - | - |
1KRW in Billions2KRW3KRW in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 44.66 | 44.7 | - | 46.45 | 48.66 | 47.84 | - | 49.67 | 50.93 | 49.22 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | 7.372 | - | 8.354 | 9.3 | 7.499 | - | 9.12 | 9.825 | 7.838 |
| Operating Margin | - | 16.49% | - | 17.99% | 19.11% | 15.68% | - | 18.36% | 19.29% | 15.92% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | 6.181 | 6.934 | - | - | 7.309 | - | - | - |
| Net margin | - | - | - | 14.93% | - | - | - | - | - | - |
| EPS | - | - | 1,030 | 1,156 | - | - | 1,243 | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 15/11/21 | 09/02/22 | 16/05/22 | 16/08/22 | 14/11/22 | 28/02/23 | 15/05/23 | 11/08/23 | 14/11/23 | 20/03/24 |
1KRW in Billions
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | 22.1 | - | 67.1 | 91.1 | 104 | 138 | 163 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 2 | - | - | - | - | 17,580 | 29,800 | 31,900 |
| ROE (net income / shareholders' equity) | 18.3% | - | 11.8% | 11.7% | 12% | 11.7% | 11.4% |
| ROA (Net income/ Total Assets) | 11.7% | - | 8.63% | 9.08% | 10.3% | 11.1% | 11.1% |
| Assets 1 | 240.8 | - | 262.8 | 274.8 | 274.8 | 277.5 | 300.5 |
| Book Value Per Share 3 | 27,796 | - | 33,801 | 37,662 | 42,172 | 46,153 | 51,048 |
| Cash Flow per Share 3 | 5,877 | - | 6,770 | 4,846 | 6,609 | 7,550 | 7,965 |
| Capex 1 | 13.2 | - | 11.9 | 8.62 | 21.3 | 9.9 | 11.2 |
| Capex / Sales | 7.84% | - | 6.91% | 4.68% | 10.86% | 4.65% | 4.82% |
| Announcement Date | 30/03/20 | 16/03/21 | 09/02/22 | 28/02/23 | 20/03/24 | - | - |
1KRW in Billions2KRW in Million3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.78% | 125M | |
| +21.59% | 44.15B | |
| +23.03% | 23.02B | |
| +18.22% | 15.33B | |
| +12.26% | 13.74B | |
| +52.55% | 12.16B | |
| -10.02% | 6.84B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.92% | 5.66B |
- Stock Market
- Equities
- A023910 Stock
- Financials Daihan Pharmaceutical Co.,Ltd.
